Back to Search Start Over

Efficacy of sucrose and povidone-iodine mixtures in peritoneal dialysis catheter exit-site care.

Authors :
Nakayama T
Morimoto K
Uchiyama K
Washida N
Kusahana E
Hama EY
Mitsuno R
Tonomura S
Yoshimoto N
Hishikawa A
Hagiwara A
Azegami T
Yoshino J
Monkawa T
Yoshida T
Yamaguchi S
Hayashi K
Source :
BMC nephrology [BMC Nephrol] 2024 May 02; Vol. 25 (1), pp. 151. Date of Electronic Publication: 2024 May 02.
Publication Year :
2024

Abstract

Background: Exit-site infection (ESI) is a common recurring complication in patients undergoing peritoneal dialysis (PD). Sucrose and povidone-iodine (SPI) mixtures, antimicrobial ointments that promote wound healing, have been used for the treatment of ulcers and burns, but their efficacy in exit-site care is still unclear.<br />Methods: This single-center retrospective observational study included patients who underwent PD between May 2010 and June 2022 and presented with episodes of ESI. Patients were divided into SPI and non-SPI groups and followed up from initial ESI onset until PD cessation, death, transfer to another facility, or June 2023.<br />Results: Among the 82 patients (mean age 62, [54-72] years), 23 were treated with SPI. The median follow-up duration was 39 months (range, 14-64), with an overall ESI incidence of 0.70 episodes per patient-year. Additionally, 43.1% of second and 25.6% of third ESI were caused by the same pathogen as the first. The log-rank test demonstrated significantly better second and third ESI-free survival in the SPI group than that in the non-SPI group (pā€‰<ā€‰0.01 and pā€‰<ā€‰0.01, respectively). In a Cox regression analysis, adjusting for potential confounders, SPI use was a significant predictor of decreased second and third ESI episodes (hazard ratio [HR], 0.22; 95% confidence interval [CI], 0.10-0.52 and HR, 0.22; 95%CI, 0.07-0.73, respectively).<br />Conclusions: Our results showed that the use of SPI may be a promising option for preventing the incidence of ESI in patients with PD.<br />Trial Registration: This study was approved by the Keio University School of Medicine Ethics Committee (approval number 20231078) on August 28, 2023. Retrospectively registered.<br /> (© 2024. The Author(s).)

Details

Language :
English
ISSN :
1471-2369
Volume :
25
Issue :
1
Database :
MEDLINE
Journal :
BMC nephrology
Publication Type :
Academic Journal
Accession number :
38698327
Full Text :
https://doi.org/10.1186/s12882-024-03591-1